David Elsley, the President & CEO of Cardiol Therapeutics Inc. (Nasdaq: CRDL | TSX: CRDL), a company dedicated to healing the heart with innovative science, joins Vince Molinari to discuss their recent milestones to kick off 2024.

Mr. Elsley shares the significance of Cardiol receiving the US FDA grant for Orphan Drug Designation for the company's lead drug candidate, CardiolRx™, aimed at treating pericarditis, including recurrent pericarditis. He speaks to the severity of recurrent pericarditis, characterized by symptoms that significantly impact patients' quality of life and physical activity. The FDA's decision to grant ODD underscores the potential of CardiolRx™ to improve the lives of individuals suffering from this condition.

They discuss Cardiol's two ongoing Phase II clinical trials targeting rare diseases of recurrent pericarditis and acute myocarditis. Additionally, Mr. Elsley shares the market opportunity for the company’s potential treatment for heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.